Effects of Tirzepatide Versus Insulin Glargine on Cystatin C–Based Kidney Function: A SURPASS-4 Post Hoc Analysis
Diabetes Care · 01.08.2023 · 46 (8) · 1501-1506
DOI: 10.2337/dc23-0261 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes Care, online erschienen am 02.06.2023. Verfasst von Hiddo J L Heerspink und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 52-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, NIDDK NIH HHS, NCATS NIH HHS.
Abstract (Originalsprache)
OBJECTIVE Tirzepatide reduces HbA1c and body weight, and creatinine-based estimated glomerular filtration rate (eGFR) decline. Unlike creatine-derived eGFR (eGFR-creatinine), cystatin C–derived eGFR (eGFR-cystatin C) is unaffected by muscle mass changes. We assessed effects of tirzepatide on eGFR-creatinine and eGFR-cystatin C. RESEARCH DESIGN AND METHODS Our primary outcome was eGFR change from baseline at 52 weeks with pooled tirzepatide (5, 10, and 15 mg) and titrated insulin glargine in adults with type 2 diabetes and high cardiovascular risk (SURPASS-4). RESULTS Least squares mean (SE) eGFR-creatinine (mL/min/1.73 m2) changes from baseline with tirzepatide and insulin glargine were −2.5 (0.38) and −3.9 (0.38) (between-group difference, 1.4 [95% CI 0.3–2.4]) and −3.5 (0.37) and −5.3 (0.37) (between-group difference, 1.8 [95% CI 0.8–2.8]) for eGFR-cystatin C. Baseline, 1-year, and 1-year change from baseline values significantly correlated between eGFR-cystatin C and eGFR-creatinine. Measures of eGFR changes did not correlate with body weight changes. CONCLUSIONS Tirzepatide slows the eGFR decline rate, supporting a kidney-protective effect.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
- The George Institute for Global Health, Sydney, New South Wales, Australia.
- School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, U.K.
- Eli Lilly and Company, Indianapolis, IN.
- Division of Nephrology, Department of Medicine, Toronto General Hospital, University Health Network, University of Toronto, Toronto, Ontario, Canada.
- Providence Health Care, University of Washington, Spokane, WA.
ORCID-Profile: Hiddo J L Heerspink, Naveed Sattar, David Z I Cherney, Katherine R Tuttle
Förderung
- NHLBI NIH HHS
- NIDDK NIH HHS
- NCATS NIH HHS
- NIMHD NIH HHS
- Eli Lilly and Company
Zitieren
APA
Heerspink, H. J. L., Sattar, N., Pavo, I., Haupt, A., Duffin, K. L., Yang, Z., Wiese, R. J., Wilson, J. M., Hemmingway, A., Cherney, D. Z. I., & Tuttle, K. R. (2023). Effects of Tirzepatide Versus Insulin Glargine on Cystatin C–Based Kidney Function: A SURPASS-4 Post Hoc Analysis. Diabetes Care, 46(8), 1501-1506. https://doi.org/10.2337/dc23-0261
Vancouver
Heerspink HJL, Sattar N, Pavo I, Haupt A, Duffin KL, Yang Z, et al. Effects of Tirzepatide Versus Insulin Glargine on Cystatin C–Based Kidney Function: A SURPASS-4 Post Hoc Analysis. Diabetes Care. 2023;46(8):1501-1506. doi:10.2337/dc23-0261
BibTeX
@article{Heerspink2023,
author = {Heerspink, Hiddo J L and Sattar, Naveed and Pavo, Imre and Haupt, Axel and Duffin, Kevin L and Yang, Zhengyu and Wiese, Russell J and Wilson, Jonathan M and Hemmingway, Andrea and Cherney, David Z I and Tuttle, Katherine R},
title = {Effects of Tirzepatide Versus Insulin Glargine on Cystatin C–Based Kidney Function: A SURPASS-4 Post Hoc Analysis},
journal = {Diabetes Care},
year = {2023},
volume = {46},
number = {8},
pages = {1501--1506},
doi = {10.2337/dc23-0261}
}
EUVIMED